In Korea, the first case of coronavirus disease 2019 (COVID-19) was confirmed on January 20, 2020. The distinguishing characteristic of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the substantial transmission potential of asymptomatic or subclinical patients. In a previous study, the viral load of SARS-CoV-2 in the upper respiratory tract of asymptomatic patients was similar to that of symptomatic patients.[@B1] However, the proportion of asymptomatic patients among the total number of patients with COVID-19 varied between studies. Among patients with mild COVID-19 in community treatment centers, asymptomatic cases accounted for 26.6% (53/199) to 58.7% (371/632).[@B2][@B3]

A seroepidemiological investigation can reveal the proportion of asymptomatic or subclinical infections in the general population. In addition, since SARS-CoV-2 is a novel coronavirus, surveillance of antibody seropositivity can provide useful information on the extent of infection and the cumulative herd immunity in the general population.[@B4] This cross-sectional study on the seroprevalence of antibodies to SARS-CoV-2 included outpatients of university hospitals in Seoul, Korea.

A total of 1,500 serum samples were collected at two hospitals in southwestern Seoul---Korea University Guro Hospital and Hallym University Kangnam Sacred Heart Hospital. In southwestern Seoul, several clusters of COVID-19 outbreaks occurred at churches, sports clubs, and a call center ([Fig. 1](#F1){ref-type="fig"}).[@B5] Moreover, a COVID-19 outbreak occurred at a large distribution center in Bucheon City, Gyeonggi-do Province, which is close to southwestern Seoul.[@B5]

Convenience samples of residual serum samples of outpatients who had visited the hospitals between May 25 and May 29, 2020 were used ([Fig. 2](#F2){ref-type="fig"}). These patients lived in six administrative districts in southwestern Seoul: Guro-gu, Yeongdeungpo-gu, Gangseo-gu, Yangcheon-gu, Gwanak-gu, and Geumcheon-gu. The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2. Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.

The electrochemiluminescence immunoassay (ECLIA) was performed to detect antibodies including immunoglobulin G (IgG) against SARS-CoV-2 using Elecsys^®^ Anti-SARS-CoV-2 (Roche, Solna, Switzerland) according to the manufacturer\'s protocol. Elecsys^®^ Anti-SARS-CoV-2 used a recombinant protein representing the nucleocapsid antigen of SARS-CoV-2 with a double-antigen sandwich assay.[@B6] Clinical sensitivity of this assay was reported as 99.5% in polymerase chain reaction (PCR)-confirmed SARS-CoV-2 cases when tested at ≥ 14 days post-PCR confirmation and specificity of Elecsys^®^ Anti-SARS-CoV-2 was reported as 99.8%.[@B6] A cutoff index (COI, signal sample/cutoff) of ≥ 1.0 was considered positive for anti-SARS-CoV-2 antibodies. Additionally, a plaque reduction neutralization test (PRNT) was performed for samples that tested positive by ECLIA. Wild-type SARS-CoV-2 (BetaCoV/Korea/KCDC03/2020) was used for PRNT, and the median neutralizing titer (ND50) was measured.

The study population comprised 48.7% men (730/1,500), and the patient age range was 0--92 years. The patients were divided into the following age groups: 0--19 years, 226 (15.1%); 20--29 years, 258 (17.2%); 30--39 years, 261 (17.4%); 40--49 years, 254 (16.9%); 50--59 years, 255 (17.0%); ≥ 60 years, 246 (16.4%). The rate of antibody positivity to SARS-CoV-2 was 0.07% (1 of 1,500; 95% confidence interval \[CI\], 0--0.44). The COI of a positive sample was 63.82 by ECLIA. ND50 was determined to be 1:764.48 using PRNT. Since the person who showed seropositivity was a 32-year-old man, seroprevalence of antibodies to SARS-CoV-2 was 0.38% (1 of 261; 95% CI, 0.02--2.45) in the 30--39-year age group.

The study hospitals were located at Guro-gu and Yeongdeungpo-gu, Seoul. Among the 25 administrative districts of Seoul, 34% of Chinese immigrants live in these two districts.[@B7] Since COVID-19 pandemic was first originated from Wuhan, China, concerns about outbreak of SARS-CoV-2 infections had been raised in these areas. However, this study indicated low-level seroprevalence of antibodies to SARS-CoV-2 in southwestern Seoul, Korea. As of May 29, 2020, the incidence of COVID-19 cases among the residents in study sites were as follows: Guro-gu, 0.009% (41/438,308); Yeongdeungpo-gu, 0.008% (34/404,766); Gangseo-gu, 0.007% (44/595,703); Yangcheon-gu, 0.006% (27/460,532); Gwanak-gu, 0.011% (59/516,662); Geumcheon-gu, 0.006% (15/251,370).[@B8]

Seroprevalence of antibodies to SARS-CoV-2 varies with country, study population, time of sampling, and laboratory testing method ([Table 1](#T1){ref-type="table"}). In cross-sectional studies conducted in outpatients in China and Japan, the seropositivity rate of antibodies to SARS-CoV-2 was 3.8% and 3.3%, respectively.[@B9][@B10] In another study, seropositivity against SARS-CoV-2 was evaluated in Hong Kong residents who were evacuated from Hubei Province, China, on March 4--5, 2020; the analysis of serum samples obtained within 13 days after evacuation revealed that 17 of 452 (3.8%) individuals were seropositive.[@B11] In a community survey in California, the United States, the seroprevalence of antibodies to SARS-CoV-2 was 4.06%.[@B12] In Lombardy, Italy, where the first COVID-19 case was identified on February 20, 2020, the seropositivity rate of neutralizing antibody against SARS-CoV-2 in blood donors was 23.3% (91/390). A seroepidemiological investigation revealed that 1.7% (5/300) of the blood donors collected before identification of the first case tested seropositive against SARS-CoV-2.[@B13] In a population-based serosurveillance study in Switzerland, 7.9% of the population showed anti-SARS-CoV-2 IgG antibodies.[@B14] In particular, the seropositivity rate was highest in the 20--49 year age group (9.9%). In the Netherlands, the seroprevalence of antibodies to SARS-CoV-2 was 2.7% among 7,361 blood donors, and seropositivity in donors aged 18--30 years was significantly higher (4.2%) than that in other age groups.[@B15] The Swedish response to the COVID-19 pandemic aimed to promote herd immunity by allowing a proportion of the population to be infected rather than containing the virus.[@B16] Nevertheless, the seroprevalence of SARS-CoV-2 antibodies was just 7.3% in Stockholm, Sweden.[@B17] The seropositive rate of SARS-CoV-2 was higher in young adults than in the elderly in Sweden---4.7%, 6.7%, and 2.7% in the age group of 0--19 years, 20--64 years; and 65--95 years, respectively.[@B17]

In Korea, seroprevalence of antibodies to SARS-CoV-2 among 198 outpatients and their guardians was 7.6% in Daegu in which more than half (56.9%, 6,881/12,088) of domestic cases with COVID-19 occurred as of August 11, 2020.[@B18] However, because of the heterogeneous and inconsistent results, the clinical performance of SARS-CoV-2 rapid lateral flow assay is still under evaluation, requiring confirmatory testing such as neutralization assay.[@B19] Considering the possible cross-reactivity from the pre-existing common cold coronaviruses (NL63, 229E, OC43 or HKU1) antibodies, it is necessary to be careful in interpreting the results.

This study has some limitations. First, a selection bias could have existed; hence, the study result might not represent the seroprevalence of antibodies to SARS-CoV-2 in the general population of southwestern Seoul, Korea. Second, epidemiological information of one person who was seropositive was not available. Third, this study was a one-time cross-sectional investigation, and seroprevalence may change as the pandemic progresses. Thus, a cross-sectional investigation should be repeated to estimate the herd immunity level.

However, this study revealed low seroprevalence of antibodies to SARS-CoV-2 in healthcare facility users in Seoul, Korea. A low seroprevalence (0.07%) reflects that the COVID-19 pandemic is relatively under control by implementation of social distancing and rigorous epidemiological investigations, including contact tracing, active testing, and patient isolation. However, low seroprevalence of SARS-CoV-2 suggests that most people are still vulnerable to SARS-CoV-2 infection. Considering the basic reproduction number of COVID-19, \> 60% of the population should be immune against SARS-CoV-2 to suppress the pandemic. Therefore, we are still at the beginning of the pandemic, and we should follow social distancing norms to prevent the explosive spread of COVID-19 until effective vaccines are available. Serosurveillance should be repeated to estimate the level of herd immunity in each country as the pandemic progress.
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###### Studies on the seroprevalence of coronavirus disease 2019
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  Countries               Source of samples                         No. of samples   Time of sampling             Laboratory method                                                                                                            Seropositivity, %                                     Reference
  ----------------------- ----------------------------------------- ---------------- ---------------------------- ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- -----------
  China                   Outpatients                               993              March 9 to April 10, 2020    Magnetic chemiluminescence enzyme immunoassay                                                                                3.8                                                   [@B9]
  Hong Kong               Asymptomatic Hubei returnees              452              March 2020                   Microneutralization assay or enzyme immunoassay                                                                              3.8                                                   [@B11]
  Italy                   Blood donors                              390              March 18 to April 6, 2020    Microneutralization assay                                                                                                    23.3                                                  [@B13]
  Japan                   Residual serum samples from outpatients   1,000            March 31 to April 7, 2020    Immunochromatographic test                                                                                                   3.3                                                   [@B10]
  Netherland              Blood donors                              7,361            April 1 to April 15, 2020    Enzyme-linked immunosorbent assay                                                                                            2.7                                                   [@B15]
  Sweden                  General population                        1,104            Late April, 2020             Not available                                                                                                                7.3 (Stockholm), 4.2 (Skåne), 3.7 (Västra Götaland)   [@B17]
  Switzerland             General population                        2,766            April 6 to May 9, 2020       Enzyme-linked immunosorbent assay                                                                                            7.9                                                   [@B14]
  United States           General population                        863              April 10 to April 14, 2020   Lateral flow immunoassay                                                                                                     4.06                                                  [@B12]
  Korea                   Outpatients and guardians                 198              May 25 to June 5, 2020       Immunochromatographic assay                                                                                                  7.6                                                   [@B18]
  Korea (present study)   Residual serum samples from outpatients   1,500            May 25 to May 29, 2020       Electrochemiluminescence immunoassay to detect antibodies including immunoglobulin G, plaque reduction neutralization test   0.07                                                  

[^1]: ^\*^Ji Yun Noh and Yu Bin Seo contributed equally to this work.
